Product and Pipeline Analysis of the Global Parkinson's Disease Therapeutics Market

USD 3,950.00

* Required Fields

USD 3,950.00


Be the first to review this product

This research service focuses on existing therapeutics and product pipeline for the treatment of Parkinson’s Disease using Dopamine Replacement Therapies, Dopamine Agonists, MAO-inhibitors, COMT-inhibitors and other pharamcolgical approaches for current global interest. This research service does not cover vaccines. A product and pipeline assessment is provided for marketed and investigational products and combination regimens for Parkinson’s Disease therapeutics. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology.

Table of Contents

Executive SummaryExecutive SummaryRecent Market DevelopmentsCompanies to WatchKey Trends in Parkinson’s Disease TherapeuticsMethodology and ScopeMethodology and ScopeIntroductionIntroductionGlobal Prevalence of Parkinson’s Disease by CountryGlobal Incidence of Parkinson’s Disease by CountryMarket OverviewMarket Overview—Segmentation by Types of TherapeuticsMarket Overview—Segmentation IllustratedMarket Overview—Segmentation Illustrated (continued)Overview of Market OpportunitiesParkinson’s Disease Therapeutics MarketCompetitive Landscape—Marketed Products and Products in DevelopmentMarketed Product Synopsis—Parkinson’s Disease Therapeutics Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued) Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued) Marketed Product Synopsis—Parkinson’s Disease Therapeutics (continued) Pipeline Synopsis—Parkinson’s Disease TherapeuticsPipeline Synopsis—Parkinson’s Disease Therapeutics- ContinuedPipeline Synopsis—Parkinson’s Disease Therapeutics- ContinuedPipeline Synopsis—Parkinson’s Disease Therapeutics- ContinuedParkinson’s Disease Therapeutics Market—Competitive Landscape: Major Ongoing TrialsCompetitive Landscape—Projected Launch Timeline for Key Pipeline DrugsCompetitive Landscape—Company Assets by Drug Pipeline ClassProduct DashboardsKey Marketed Products Dashboard: Stalevo (Carbidopa-Levodopa-Entacapone)—Orion CorporationKey Marketed Products Dashboard: Sinemet (carbidopa-levodopa)—Merck & CoKey Marketed Products Dashboard: Azilect (Rasagiline) By TEVA PharmaceuticalsKey Marketed Products Dashboard: Zelapar (Selagiline) By Valeant PharmaceuticalsKey Marketed Products Dashboard: Mirapex (Pramipexole) By Boehringer IngelheimKey Marketed Products Dashboard: Neupro (Rotigotine) By UCB Inc. and Schwarz PharmaKey Marketed Products Dashboard: Requip (Ropinirole) By Glaxo SmithKlineKey Phase 3 Products Dashboard:Nouriast® (Istradefylline) By Kyowa Hakko KirinKey Phase 2 Products Dashboard:Ampyra® (dalfampridine) By Acorda TherapeuticsKey Phase 3 Products Dashboard:Duodopa® (sinemet) By AbbVie PharmaceuticalConclusions and RecommendationsConclusionConclusions (Continued)Legal DisclaimerAppendixDecision Support Database—Global Population with Parkinson’s DiseaseDecision Support Database—Global Population with Parkinson’s Disease (continued)The Frost & Sullivan StoryWho is Frost & SullivanWhat Makes Us UniqueTEAM MethodologyOur Global Footprint 40+ Offices

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.